A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma
Other specific eligibility criteria may apply. Examination by the investigator is
necessary to fully determine eligibility.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Safety and identification of dose-limiting toxicities
United States: Food and Drug Administration
|Mayo Clinic||Scottsdale, Arizona|
|Scottsdale Healthcare||Scottsdale, Arizona 85251|